Vakil D, McCaughan G
A W Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney.
Aust Fam Physician. 1998 Sep;27(9):780-6.
Hepatitis C is common and most patients with hepatitis C will develop chronic hepatitis. A significant proportion of patients develop cirrhosis and there is a definite but unquantified risk of hepatocellular carcinoma.
This article examines the latest treatments available for hepatitis C.
Interferon alfa is the only currently proven treatment but recent trials suggest that combination therapy with Ribavirin improves sustained long term response rate. Patients should be counselled regarding the mode of transmission of the virus. Patients with cirrhosis should be screened for hepatocellular carcinoma and liver transplantation should be considered for patients with decompensated disease.
丙型肝炎很常见,大多数丙型肝炎患者会发展为慢性肝炎。相当一部分患者会发展为肝硬化,肝细胞癌的发生风险明确但难以量化。
本文探讨了丙型肝炎的最新治疗方法。
目前,α干扰素是唯一经证实有效的治疗药物,但近期试验表明,利巴韦林联合治疗可提高长期持续应答率。应向患者提供有关病毒传播方式的咨询。应对肝硬化患者进行肝细胞癌筛查,对于失代偿性疾病患者应考虑进行肝移植。